Last reviewed · How we verify
chlorproguanil-dapsone-artesunate
Chlorproguanil-dapsone-artesunate is a combination antimalarial medication that works by targeting the malaria parasite's metabolic pathways and disrupting its ability to synthesize nucleic acids.
Chlorproguanil-dapsone-artesunate is a combination antimalarial medication that works by targeting the malaria parasite's metabolic pathways and disrupting its ability to synthesize nucleic acids. Used for Treatment of uncomplicated Plasmodium falciparum malaria, Prevention of malaria in areas with chloroquine-resistant strains.
At a glance
| Generic name | chlorproguanil-dapsone-artesunate |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Antimalarial |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Chlorproguanil inhibits dihydrofolate reductase, an enzyme essential for the malaria parasite's nucleic acid synthesis. Dapsone has antifolate properties, while artesunate is a potent antimalarial compound that targets the parasite's hemoglobin degradation pathway.
Approved indications
- Treatment of uncomplicated Plasmodium falciparum malaria
- Prevention of malaria in areas with chloroquine-resistant strains
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania (PHASE3)
- Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria (PHASE2)
- Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria (PHASE3)
- Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria (PHASE3)
- Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children (PHASE3)
- Intermittent Preventive Treatment With Antimalarials in Kenyan Infants (NA)
- Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi (PHASE4)
- Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- chlorproguanil-dapsone-artesunate CI brief — competitive landscape report
- chlorproguanil-dapsone-artesunate updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI